COMMD5 inhibits malignant behavior of renal cancer cells

Jin Ikeda; Hiroyuki Matsuda; Maiko Ogasawara; Yukimoto Ishii; Kenya Yamaguchi; Satoru Takahashi; Noboru Fukuda; Yoshikazu Masuhiro; Morito Endo; Masayoshi Soma; Pavel Hamet; Johanne Tremblay

doi:10.21873/anticanres.15061

COMMD5 inhibits malignant behavior of renal cancer cells

Jin Ikeda, Hiroyuki Matsuda, Maiko Ogasawara, Yukimoto Ishii, Kenya Yamaguchi, Satoru Takahashi, Noboru Fukuda, Yoshikazu Masuhiro, Morito Endo, Masayoshi Soma, Pavel Hamet, Johanne Tremblay

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background/Aim: Copper metabolism MURR1 domain-containing 5 (COMMD5) is mainly expressed in renal tubules (RTs), where it facilitates re-differentiation of injured RTs. We reported that COMMD5 regulates the expression of epidermal growth factor receptor by participating in its endocytic membrane trafficking, thus inhibiting tumor growth. Here we aimed to determine the role of COMMD5 in malignant phenotypes of renal cell carcinoma (RCC). Materials and Methods: The associations between COMMD5 levels in RTs adjacent to RCC tumors in patients and their clinicopathologic characteristics were evaluated, and the effects of COMMD5 on cancer stemness in RCC cells were investigated. Results: Low COMMD5 levels in RTs correlated with high tumorigenesis and poor patient outcomes. COMMD5 overexpression in RCC cells reduced the proportion of cancer stem cell-like cells and their malignant phenotypes, including proliferation, invasion and sphere formation. Secreted COMMD5 from RT cells also reduced malignant phenotypes. Conclusion: COMMD5 might suppress malignant phenotypes of RCC, thus inhibiting tumor development and improving patient prognosis.

Original language	English
Pages (from-to)	2805-2815
Number of pages	11
Journal	Anticancer Research
Volume	41
Issue number	6
DOIs	https://doi.org/10.21873/anticanres.15061
Publication status	Published - Jun 2021

Keywords

COMMD5
Cancer stem cell
Metastasis and recurrence
Renal cell carcinoma
Renal tubules

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15061

Cite this

@article{4e9e0fa7e0244ccc81ad696446c9ba7a,

title = "COMMD5 inhibits malignant behavior of renal cancer cells",

abstract = "Background/Aim: Copper metabolism MURR1 domain-containing 5 (COMMD5) is mainly expressed in renal tubules (RTs), where it facilitates re-differentiation of injured RTs. We reported that COMMD5 regulates the expression of epidermal growth factor receptor by participating in its endocytic membrane trafficking, thus inhibiting tumor growth. Here we aimed to determine the role of COMMD5 in malignant phenotypes of renal cell carcinoma (RCC). Materials and Methods: The associations between COMMD5 levels in RTs adjacent to RCC tumors in patients and their clinicopathologic characteristics were evaluated, and the effects of COMMD5 on cancer stemness in RCC cells were investigated. Results: Low COMMD5 levels in RTs correlated with high tumorigenesis and poor patient outcomes. COMMD5 overexpression in RCC cells reduced the proportion of cancer stem cell-like cells and their malignant phenotypes, including proliferation, invasion and sphere formation. Secreted COMMD5 from RT cells also reduced malignant phenotypes. Conclusion: COMMD5 might suppress malignant phenotypes of RCC, thus inhibiting tumor development and improving patient prognosis.",

keywords = "COMMD5, Cancer stem cell, Metastasis and recurrence, Renal cell carcinoma, Renal tubules",

author = "Jin Ikeda and Hiroyuki Matsuda and Maiko Ogasawara and Yukimoto Ishii and Kenya Yamaguchi and Satoru Takahashi and Noboru Fukuda and Yoshikazu Masuhiro and Morito Endo and Masayoshi Soma and Pavel Hamet and Johanne Tremblay",

year = "2021",

month = jun,

doi = "10.21873/anticanres.15061",

language = "English",

volume = "41",

pages = "2805--2815",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - COMMD5 inhibits malignant behavior of renal cancer cells

AU - Ikeda, Jin

AU - Matsuda, Hiroyuki

AU - Ogasawara, Maiko

AU - Ishii, Yukimoto

AU - Yamaguchi, Kenya

AU - Takahashi, Satoru

AU - Fukuda, Noboru

AU - Masuhiro, Yoshikazu

AU - Endo, Morito

AU - Soma, Masayoshi

AU - Hamet, Pavel

AU - Tremblay, Johanne

PY - 2021/6

Y1 - 2021/6

N2 - Background/Aim: Copper metabolism MURR1 domain-containing 5 (COMMD5) is mainly expressed in renal tubules (RTs), where it facilitates re-differentiation of injured RTs. We reported that COMMD5 regulates the expression of epidermal growth factor receptor by participating in its endocytic membrane trafficking, thus inhibiting tumor growth. Here we aimed to determine the role of COMMD5 in malignant phenotypes of renal cell carcinoma (RCC). Materials and Methods: The associations between COMMD5 levels in RTs adjacent to RCC tumors in patients and their clinicopathologic characteristics were evaluated, and the effects of COMMD5 on cancer stemness in RCC cells were investigated. Results: Low COMMD5 levels in RTs correlated with high tumorigenesis and poor patient outcomes. COMMD5 overexpression in RCC cells reduced the proportion of cancer stem cell-like cells and their malignant phenotypes, including proliferation, invasion and sphere formation. Secreted COMMD5 from RT cells also reduced malignant phenotypes. Conclusion: COMMD5 might suppress malignant phenotypes of RCC, thus inhibiting tumor development and improving patient prognosis.

AB - Background/Aim: Copper metabolism MURR1 domain-containing 5 (COMMD5) is mainly expressed in renal tubules (RTs), where it facilitates re-differentiation of injured RTs. We reported that COMMD5 regulates the expression of epidermal growth factor receptor by participating in its endocytic membrane trafficking, thus inhibiting tumor growth. Here we aimed to determine the role of COMMD5 in malignant phenotypes of renal cell carcinoma (RCC). Materials and Methods: The associations between COMMD5 levels in RTs adjacent to RCC tumors in patients and their clinicopathologic characteristics were evaluated, and the effects of COMMD5 on cancer stemness in RCC cells were investigated. Results: Low COMMD5 levels in RTs correlated with high tumorigenesis and poor patient outcomes. COMMD5 overexpression in RCC cells reduced the proportion of cancer stem cell-like cells and their malignant phenotypes, including proliferation, invasion and sphere formation. Secreted COMMD5 from RT cells also reduced malignant phenotypes. Conclusion: COMMD5 might suppress malignant phenotypes of RCC, thus inhibiting tumor development and improving patient prognosis.

KW - COMMD5

KW - Cancer stem cell

KW - Metastasis and recurrence

KW - Renal cell carcinoma

KW - Renal tubules

UR - http://www.scopus.com/inward/record.url?scp=85107687953&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15061

DO - 10.21873/anticanres.15061

M3 - Article

C2 - 34083270

AN - SCOPUS:85107687953

SN - 0250-7005

VL - 41

SP - 2805

EP - 2815

JO - Anticancer Research

JF - Anticancer Research

IS - 6

ER -

COMMD5 inhibits malignant behavior of renal cancer cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this